Effects of a green tea extract, Polyphenon E, on systemic biomarkers of growth factor signalling in women with hormone receptor‐negative breast cancer. Issue 3 (19th March 2014)

• Record Type: Journal Article
• Authors: Crew, K. D.; Ho, K. A.; Brown, P.; Greenlee, H.; Bevers, T. B.; Arun, B.; Sneige, N.; Hudis, C.; McArthur, H. L.; Chang, J.; Rimawi, M.; Cornelison, T. L.; Cardelli, J.; Santella, R. M.; Wang, A.; Lippman, S. M.; Hershman, D. L.
• Is Part Of: Journal of human nutrition and dietetics. Volume 28:Issue 3(2015)
• Page Start: 272
• Page End: 282
• Publication Date: 2014-03-19
• Subjects: Dietetics -- Periodicals; Nutrition -- Periodicals; 613.205
• DOI: 10.1111/jhn.12229
• Languages: English
• ISSNs: 0952-3871

Abstract

<abstract abstract-type="main" id="jhn12229-abs-0001"> <title>Abstract</title> <sec id="jhn12229-sec-0001" sec-type="section"> <title>Background</title> <p>Observational and experimental data support a potential breast cancer chemopreventive effect of green tea.</p> </sec> <sec id="jhn12229-sec-0002" sec-type="section"> <title>Methods</title> <p>We conducted an ancillary study using archived blood/urine from a phase IB randomised, placebo‐controlled dose escalation trial of an oral green tea extract, Polyphenon E (Poly E), in breast cancer patients. Using an adaptive trial design, women with stage I–III breast cancer who completed adjuvant treatment were randomised to Poly E 400 mg (<italic>n </italic>=<italic> </italic>16), 600 mg (<italic>n </italic>=<italic> </italic>11) and 800 mg (<italic>n </italic>=<italic> </italic>3) twice daily or matching placebo (<italic>n </italic>=<italic> </italic>10) for 6 months. Blood and urine collection occurred at baseline, and at 2, 4 and 6 months. Biological endpoints included growth factor [serum hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF)], lipid (serum cholesterol, triglycerides), oxidative damage and inflammatory biomarkers.</p> </sec> <sec id="jhn12229-sec-0003" sec-type="section"> <title>Results</title> <p>From July 2007‐August 2009, 40 women were enrolled and 34 (26 Poly E, eight placebo) were evaluable for biomarker endpoints. At 2 months, the Poly E group (all dose levels combined) compared to placebo had a significant decrease in mean serum HGF levels (−12.7% versus +6.3%, <italic>P</italic> = 0.04). This trend persisted at 4 and 6 months but was no longer statistically significant. For the Poly E group, serum VEGF decreased by 11.5% at 2 months (<italic>P</italic> = 0.02) and 13.9% at 4 months (<italic>P</italic> = 0.05) but did not differ compared to placebo. At 2 months, there was a trend toward a decrease in serum cholesterol with Poly E (<italic>P</italic> = 0.08). No significant differences were observed for other biomarkers.</p> </sec> <sec id="jhn12229-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our findings suggest potential mechanistic actions of tea polyphenols in growth factor signalling, angiogenesis and lipid metabolism.</p> </sec> </abstract>